Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 3, 2013Stroke

Patients carrying 1 or 2 CYP2C19 loss-of-function alleles had significantly smaller reductions in ADP-induced platelet aggregation and worse NIHSS and mRS scores at 3 and 6 months compared to non-carriers.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Do CYP2C19 loss-of-function alleles reduce the antiplatelet effect and clinical efficacy of clopidogrel in patients with acute ischemic stroke?

Population

259 patients with acute ischemic stroke in China

Comparison

Clopidogrel treatment in patients carrying 1 or… vs Clopidogrel treatment in patients carrying no…

Design

Cohort

Follow-up

6 months

Authors

DJDongmei JiaZCZhibin ChenMZMeijuan Zhang

Discussion

Loading...

Member takes

Overview

May attenuate clopidogrel efficacy in acute ischemic stroke; hypothesis-generating for genotype-guided trials.

Structured PICO

Do CYP2C19 loss-of-function alleles reduce the antiplatelet effect and clinical efficacy of clopidogrel in patients with acute ischemic stroke?

P
Population
259 patients with acute ischemic stroke in China
I
Intervention
Clopidogrel treatment in patients carrying 1 or 2 CYP2C19 loss-of-function alleles (*2, *3)
C
Comparator
Clopidogrel treatment in patients carrying no CYP2C19 loss-of-function alleles
O
Outcome
Adenosine diphosphate-induced platelet aggregation, National Institutes of Health Stroke Scale (NIHSS), and modified Rankin Scale (mRS) at 3 and 6 monthssurrogate

CYP2C19 loss-of-function alleles are associated with reduced antiplatelet response to clopidogrel and worse clinical outcomes in patients with acute ischemic stroke.

Cite This Study

Jia et al. (2013) studied this question.

synapsesocial.com/papers/6a7d31f7166e996abdd5a668https://doi.org/10.1161/strokeaha.113.000823
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response2015 · 45 citations
  2. 2CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients2013
  3. 3Cytochrome P450 <i>2C19</i> Genotypes and Clopidogrel in Patients With Ischemic Stroke2025 · 9 citations
  4. 4Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors2016 · 18 citations
  5. 5Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China2023 · 3 citations